DYAI
Price
$0.46
Change
+$0.03 (+6.98%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
18.63M
40 days until earnings call
Intraday BUY SELL Signals
MDGL
Price
$499.44
Change
-$0.27 (-0.05%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
11.95B
27 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DYAI vs MDGL

DYAI vs MDGL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DYAI vs. MDGL commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DYAI is a StrongBuy and MDGL is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
DYAI vs MDGL: Fundamental Ratings
DYAI
MDGL
OUTLOOK RATING
1..100
264
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
10017
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9157
P/E GROWTH RATING
1..100
55100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (66) in the Pharmaceuticals Other industry is in the same range as DYAI (98) in the Biotechnology industry. This means that MDGL’s stock grew similarly to DYAI’s over the last 12 months.

MDGL's Profit vs Risk Rating (17) in the Pharmaceuticals Other industry is significantly better than the same rating for DYAI (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than DYAI’s over the last 12 months.

MDGL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as DYAI (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to DYAI’s over the last 12 months.

MDGL's Price Growth Rating (57) in the Pharmaceuticals Other industry is somewhat better than the same rating for DYAI (91) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than DYAI’s over the last 12 months.

DYAI's P/E Growth Rating (55) in the Biotechnology industry is somewhat better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that DYAI’s stock grew somewhat faster than MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DYAIMDGL
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 5 days ago
76%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
79%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
69%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (DYAI: $0.43 vs. MDGL: $499.71)
Brand notoriety: DYAI and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DYAI: 40% vs. MDGL: 72%
Market capitalization -- DYAI: $18.63M vs. MDGL: $11.95B
DYAI [@Biotechnology] is valued at $18.63M. MDGL’s [@Biotechnology] market capitalization is $11.95B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DYAI’s FA Score shows that 0 FA rating(s) are green while MDGL’s FA Score has 1 green FA rating(s).

  • DYAI’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than DYAI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DYAI’s TA Score shows that 4 TA indicator(s) are bullish while MDGL’s TA Score has 4 bullish TA indicator(s).

  • DYAI’s TA Score: 4 bullish, 4 bearish.
  • MDGL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, DYAI is a better buy in the short-term than MDGL.

Price Growth

DYAI (@Biotechnology) experienced а -1.29% price change this week, while MDGL (@Biotechnology) price change was -2.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

DYAI is expected to report earnings on Nov 11, 2026.

MDGL is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
DYAI
Daily Signal:
Gain/Loss:
MDGL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TLNC10.270.03
+0.29%
Talon Capital Corp
WLK62.470.16
+0.26%
Westlake Corp
ITHAU10.35N/A
N/A
ITHAX Acquisition Corp III+
NEXT6.31-0.04
-0.63%
NextDecade Corp
COLA2.86-4.44
-60.82%
Columbus Acquisition Corp

DYAI and

Correlation & Price change

A.I.dvisor tells us that DYAI and MDGL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DYAI and MDGL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYAI
1D Price
Change %
DYAI100%
-3.37%
MDGL - DYAI
29%
Poorly correlated
-0.84%
VRAX - DYAI
29%
Poorly correlated
+2.75%
FATE - DYAI
28%
Poorly correlated
-2.95%
BBLG - DYAI
28%
Poorly correlated
-4.29%
TAOX - DYAI
27%
Poorly correlated
-3.09%
More